ADG20

DRUG2 trials

Sponsors

Invivyd, Inc.

Conditions

COVID-19

Phase 2

Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19

TerminatedNCT04805671

Invivyd, Inc.COVID-19

Start: 2021-07-26End: 2022-11-03Updated: 2024-02-06

Evaluation of ADG20 for the Prevention of COVID-19

TerminatedNCT04859517

Invivyd, Inc.COVID-19

Start: 2021-04-27End: 2022-11-04Updated: 2024-08-20

Related Papers

Safety first: should the high tolerability of intramuscular anti-spike COVID-19 monoclonal antibody change our expectations of vaccine safety?

medRxiv2026-05-08

1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention

Open Forum Infectious Diseases2023-11-272 citations

Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)

Open Forum Infectious Diseases2023-06-1320 citations

Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron

Open Forum Infectious Diseases2023-05-2412 citations

1088. A Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment of Coronavirus Disease (COVID-19)

Open Forum Infectious Diseases2021-11-012 citations

633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)

Open Forum Infectious Diseases2021-11-012 citations

1089. Use of a Whole-Body Quantitative System Pharmacology Physiologically-Based Pharmacokinetic (QSP/PBPK) Model to Support Dose Selection of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Prevention of Coronavirus Disease (COVID-19)

Open Forum Infectious Diseases2021-11-011 citations